肌层浸润性膀胱癌术后应用不同辅助方法治疗的临床效果观察  

The Clinical Effect of Different Adjuvant Therapy for Musculocutaneous Invasive Bladder Cancer

作　　者：张国颖[1] 雷永虹[1] 秦扬[1] 王启林[1] 白宇[1] 杨勇[1] 赵斌[1] 杨李波 ZHANG Guoying;LEI Yonghong;QIN Yang;WANG Qilin;BAI Yu;YANG Yong;ZHAO Bin;YANG Libo(Department of Urology, Yunnan Provincial Cancer Hospital, Kunming Yunnan 650000, Chin)

机构地区：[1]云南省肿瘤医院泌尿外科,云南昆明650000

出　　处：《中国继续医学教育》2018年第4期90-92,共3页China Continuing Medical Education

摘　　要：目的探究肌层浸润性膀胱癌术后应用不同辅助方法治疗的临床效果。方法选择2013年1月—2016年8月我院68例肌层浸润性膀胱癌患者为研究对象,根据术后治疗方式的不同分为对照组与观察组,对照组行吡柔比星灌注治疗,观察组在此基础上联合吉西他滨交替灌注,比较两组治疗效果。结果观察组治疗1年后复发率低于对照组、KPS评分高于对照组(P<0.01),并发症几率比较,差异无统计学意义(P>0.05)。结论肌层浸润性膀胱癌术后应用吡柔比星灌注联合吉西他滨交替灌注治疗效果显著,能有效降低患者的复发率。Objective To explore the clinical effect of different adjuvant therapy for musculocutaneous invasive bladder cancer. Methods 68 cases of invasive bladder cancer in our hospital from January 2013 to August 2016 were selected as the subjects. According to the different methods of treatment, the control group was divided into the control group and the observation group, and the control group was treated with pirubicin. On this basis, the observation group combined with gemcitabine perfusion, and compared the effect of the two groups. Results After 1 year of treatment, the recurrence rate of the observation group was lower than that of the control group and the KPS score was higher than that of the control group （P 〈 0.01）. There was no statistically signifcant difference in the incidence of complications （P 〉 0.05）. Conclusion The effect of pirarubicin perfusion combined with gemcitabine in the treatment of invasive bladder cancer can effectively reduce the recurrence rate of the patients.

关 键 词：肌层浸润性膀胱癌 辅助方法 化疗 吉西他滨 

分 类 号：R694[医药卫生—泌尿科学]